Eli Lilly posted what analysts called a 'blowout quarter,' fueled by robust international sales of its diabetes drug Mounjaro. The company responded by raising its full-year guidance for both profit and revenue, signaling confidence in its growth trajectory.
While Mounjaro's performance overseas drove the upside, attention is now shifting to the launch of Lilly's next-generation obesity drug, Foundayo. The company has positioned Foundayo as a key growth driver in the increasingly competitive weight-loss market.